Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitwise Crypto Industry Innovators ETF vs Quest Diagnostics Inc — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $22.59, while Quest Diagnostics Inc trades at $238.22 (market cap $26.21B). The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Bitwise Crypto Industry Innovators ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| BITQ | DGX | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $30.43 | $238.50 |
52-Week Low | $16.74 | $173.49 |
Market Cap | — | $26.21B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $22.77, up 2.59% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks available fundamental data such as P/E, revenue, or earnings metrics. Recent news highlights institutional interest in crypto ETFs, though BITQ itself is a US stock with no direct crypto operations.
The outlook remains cautious due to bearish technicals and absent financials. Risks include market volatility and competition, while opportunities hinge on future earnings clarity. Investors should await fundamental updates for a clearer investment thesis.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
